The pharmaceutical industry rose slightly and CXO leaders fell together Hangzhou Tigermed Consulting Co.Ltd(300347) market value ranking fell to the Ninth “weekly list of pharmaceutical industry”

The pharmaceutical index rose slightly by 0.67% to close at 1252796 this week. On Friday, 104 stocks rose, 115 fell and 11 were flat.

Among the top ten pharmaceutical companies by market value, only Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Zhejiang Nhu Company Ltd(002001) and Beijing Tongrentang Co.Ltd(600085) rose this week. Among them, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) rose the most, with a weekly increase of 6.25% to close at 44.73 yuan / share, with a total market value of 114638 billion yuan, rising one place to No. 4 in the market value ranking; The biggest decline this week was Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , with a weekly decline of 11.43% to close at 316.16 yuan / share. The total market value was 190745 billion yuan, and the market value ranking remained unchanged.

In terms of sectors, the cro index rose slightly by 0.42% this week, but the share price of CXO leading enterprises fell significantly. Among them, Hangzhou Tigermed Consulting Co.Ltd(300347) fell the most, with a weekly decline of 8.22%. The share price fell below the 100 yuan mark to close at 96.19 yuan / share, with a total market value of 83.920 billion yuan. The market value fell two places to No. 9 Pharmaron Beijing Co.Ltd(300759) decreased by 6.16%, Wuxi Apptec Co.Ltd(603259) decreased by 1.44%, and Asymchem Laboratories (Tianjin) Co.Ltd(002821) decreased by 0.58%.

During the seven days from February 27 to March 4, four pharmaceutical companies disclosed their 2021 annual reports, namely Sino Biological Inc(301047) , Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) , Yantai Zhenghai Bio-Tech Co.Ltd(300653) and Jiangsu Kanion Pharmaceutical Co.Ltd(600557) .

On February 27, Sino Biological Inc(301047) disclosed the performance report of 2021 Sino Biological Inc(301047) is a biotechnology company engaged in the R & D, production, sales and technical services of biological reagents. Its main business includes products such as recombinant protein, antibody, gene and culture medium, as well as services such as the development of recombinant protein and antibody and biological analysis and detection. The year-on-year business income of virus related . The net profit attributable to the parent company was 720 million yuan, a year-on-year decrease of 36.15%.

On Friday, Sino Biological Inc(301047) held a performance presentation meeting. Zhang Jie, general manager of Sino Biological Inc(301047) and Feng Tao, chief financial officer and Secretary of the board of directors attended the presentation meeting. At the meeting, the company said that the overall performance decline of the company in 2021 was mainly due to covid-19 virus related businesses affected by epidemic changes, prevention and control policies, market competition and other factors, but non covid-19 virus related businesses maintained sustained and rapid growth. The company expects that the company’s non covid-19 virus related business revenue will maintain sustained and rapid growth in 2022; Covid-19 virus related business income is affected by epidemic changes, prevention and control policies, market competition and other factors, and there is uncertainty.

According to the data, from 2019 to 2021, Sino Biological Inc(301047) non covid-19 products achieved revenue of 181 million yuan, 254 million yuan and 359 million yuan respectively. Sino Biological Inc(301047) rose 2.73% this week and closed at 342.25 yuan / share on Friday.

In addition, Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) disclosed in the annual report that the net profit attributable to the parent company was 105.7 million yuan, a year-on-year increase of 45.81% Yantai Zhenghai Bio-Tech Co.Ltd(300653) net profit attributable to parent company was 168.6 million yuan, with a year-on-year increase of 42.44% Jiangsu Kanion Pharmaceutical Co.Ltd(600557) 2021 net profit attributable to parent company was 320.5 million yuan, with a year-on-year increase of 21.92%.

This week, the traditional Chinese medicine index rose 0.21% and the innovative drug index fell 0.22%.

- Advertisment -